InvestorsHub Logo
Followers 51
Posts 4564
Boards Moderated 0
Alias Born 12/14/2009

Re: The_Q post# 17642

Wednesday, 01/09/2019 8:52:33 AM

Wednesday, January 09, 2019 8:52:33 AM

Post# of 43747
Let me help you as a professional in the medical field:
1. Multikine is indicated as first in line treatment of H&N cancer and NOT for recurrent H&N cancer
2. Multikine is indicated for use PRIOR to surgery and possible chemo ...

Therefore Multikine is unique and as groundbreaking as CAR-T cells. If successful in P3, we may expect a buyout for not less than $4 billion
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CVM News